Hepatitis C News

The European Association for the Study of the Liver responded with serious concern to a systematic review published by the Cochrane Group Review that stated, direct acting antivirals “do not seem to have any effects on risk of serious adverse events [but] we could neither confirm nor reject that DAAs had any clinical effects.”

AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use for its ribavirin-free regimen Maviret for the treatment of chronic hepatitis C of all genotypes, according to a press release.

Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for its direct-acting antiviral regimen sofosbuvir-velpatasvir-voxilaprevir, or Vosevi, according to a press release.

Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic manifestations, according to results of a recently published study. The researchers suggested this means greater impact from direct-acting antiviral treatments.

The most significant risk factor for mortality in patients with hepatitis C-related cirrhosis and successfully treated hepatocellular carcinoma was hepatic decompensation within the first year of follow-up, according to a recently published study.

Direct-acting antiviral treatment in patients with hepatitis C and cirrhosis was most cost-effective and cost-saving pre-liver transplant among those with a MELD score of 21 or less, but post-liver transplant among those with a MELD score over 21, according to a recent study.

An electronic health record clinical decision support tool significantly increased hepatitis C virus screening, as well as follow-up testing and linkage to care among members of the baby boomer generation, according to recently published findings.

A recent report from the O’Neill Institute for National and Global Health Law at Georgetown University provides key recommendations for the potential elimination of hepatitis C in the U.S., based upon an expert consultation of 35 diverse stakeholders, including HCV medical and non-medical providers, patient advocates, epidemiologists, and federal HCV policy and program staff.

Patients with hepatitis C and HIV coinfection had high rates of sustained virologic response in an urban clinical setting with the use of standard nurse and pharmacist adherence support programs, according to results of a recent study.

Regulus Therapeutics announced its plans to discontinue development of RG-101 for hepatitis C, according to a press release. Additionally, the company is initiating a phase 2 study for an Alport syndrome treatment, an investigational new drug for autosomal dominant polycystic kidney disease and discontinuing two other drug candidates.